Abstract
Aim: To evaluate new biomarkers such as YKL-40, preptin, and nitric oxide (NO) in patients with diabetes and to assess its relation to cardiorenal injury.
Patients and methods: The study included 62 patients with type 1 diabetes and 30 healthy volunteers. Blood sample was taken for assessment of glycosylated hemoglobin, lipid profile, YKL-40, preptin, and NO. Also, urine sample was taken for analysis of albumin/creatinine ratio. Echocardiography was also done.
Results: NO was lower, whereas YKL-40, preptin, and albumin/creatinine ratio were significantly higher in patients with diabetes. NO had a significant negative correlation with LVEDD, LVESD, PWT, LV mass, YKL-40, preptin, and albumin/creatinine ratio. YKL-40 had a significant positive correlation with waist/height ratio, preptin and negative correlation with E/A ratio. Stepwise multiple regression revealed that E/A ratio is the only parameter related to YKL-40. On the contrary, NO and systolic blood pressure are related to preptin.
Conclusion: A significant reduction of NO and elevation of YKL-40 and preptin was found in patients with diabetes. A decrease in NO is associated with diastolic dysfunction, LV hypertrophy, and renal impairment, whereas YKL-40 is associated with diastolic dysfunction. An increase in preptin level was associated with hypertension.
References
1. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009;32:323–28.10.2337/dc08-1144Search in Google Scholar PubMed PubMed Central
2. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 2006;55:221–73.10.1007/s00011-006-0076-ySearch in Google Scholar PubMed
3. Millis AJ, Hoyle M, Kent L. In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 1986;127:366–72.10.1002/jcp.1041270304Search in Google Scholar PubMed
4. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168–73.10.1006/excr.1999.4511Search in Google Scholar PubMed
5. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995;270:13076–83.10.1074/jbc.270.22.13076Search in Google Scholar PubMed
6. Baykus Y, Gurates B, Aydin S, Celik H, Kavak B, et al. Changes in serum obestatin, preptin and ghrelins in patients with gestational diabetes mellitus. Clin Biochem 2012;45:198–202.10.1016/j.clinbiochem.2011.08.1131Search in Google Scholar PubMed
7. Egido EM, Hernandez R, Marco J, Silvestre RA. Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. Regul Pept 2009;152:61–6.10.1016/j.regpep.2008.08.003Search in Google Scholar PubMed
8. Buchanan CM, Phillips AR, Cooper GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 2007;360:431–39.10.1042/bj3600431Search in Google Scholar
9. Yang G, Li L, Chen W, Boden G, Li K. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Ann Med 2009;41:52–6.10.1080/07853890802244142Search in Google Scholar PubMed
10. Toda N, Takeshi Imamura T, Okamura T. Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus. Pharmacol Ther 2010;127:189–209.10.1016/j.pharmthera.2010.04.009Search in Google Scholar PubMed
11. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228–34.10.1172/JCI114688Search in Google Scholar
12. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001;22:36–52.10.1210/edrv.22.1.0417Search in Google Scholar
13. Cosentino F, Lüscher TF. Effects of blood pressure and glucose on endothelial function. Curr Hypertens Rep 2001;3:79–88.10.1007/s11906-001-0085-8Search in Google Scholar
14. Tanner JM, Hiernaux J, Jarman S. Growth and physical studies. In: Weiner JS, Lourie JA, editors. Human biology: a guide to field methods. Oxford: Blackwell Scientific Publications, 1969:3–41.Search in Google Scholar
15. Cameron N. The methods of auxological anthropology. In: Falkner F, Tanner JM, editors. Human growth 3 methodology. New York: Plenum Press, 1986:3–46.Search in Google Scholar
16. Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 2008;21:922–34.10.1016/j.echo.2008.02.006Search in Google Scholar
17. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450–58.10.1016/0002-9149(86)90771-XSearch in Google Scholar
18. Cori AD, Di BV, Miccoli R, Talini E, Palagi C, et al. Left ventricular function in normotensive young adults with well controlled type 1 diabetes mellitus. Am J Cardiol 2007;99:84–90.10.1016/j.amjcard.2006.07.063Search in Google Scholar PubMed
19. Palmieri V, Capaldo B, Russo C, Laccarino M, Pezzullo S, et al. Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: insights from echocardiography and exercise cardiac performance evaluation. Diabetes Res Clin Pract 2008;79:262–68.10.1016/j.diabres.2007.09.014Search in Google Scholar PubMed
20. Abd El Dayem SM, Battah AA. Effect of glycemic control on the progress of left ventricular hypertrophy and diastolic dysfunction in children with type I diabetes mellitus. Anadolu Kardiyol Derg 2012;12:498–507.Search in Google Scholar
21. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005;109:143–59.10.1042/CS20050025Search in Google Scholar PubMed
22. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD, et al. Markers of inflammation is cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370–78.10.1007/s00125-004-1628-8Search in Google Scholar PubMed
23. Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008;31:1170–76.10.2337/dc07-1960Search in Google Scholar PubMed
24. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006;55:53–59.10.1007/s00011-005-0010-8Search in Google Scholar PubMed
25. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, et al. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol 2010;143: 35–42.10.1016/j.ijcard.2009.01.043Search in Google Scholar PubMed
26. Hempen M, Kopp HP, Elhenicky M, Hobaus C, Brix JM, et al. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 2009;19:1557–63.10.1007/s11695-009-9917-4Search in Google Scholar PubMed
27. Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plomgaard P, et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008;57:3078–82.10.2337/db08-0182Search in Google Scholar PubMed PubMed Central
28. Rathcke CN, Vestergaard H. YKL-40 – an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009;8:61.10.1186/1475-2840-8-61Search in Google Scholar PubMed PubMed Central
29. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172–209.Search in Google Scholar
30. Aydin S. Discovery of ghrelin hormone: research and clinical applications. Turk J Biochem 2007;32:76–89.Search in Google Scholar
31. Aslan M, Celik O, Karsavuran N, Celik N, Dogan DG, et al. Maternal serum and cord blood preptin levels in gestational diabetes mellitus. J Perinatol 2011;31:350–55.10.1038/jp.2010.125Search in Google Scholar PubMed
32. Sibal L, Agarwal SC, Schwedhelm E, Lüneburg N, Böger RH, et al. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol 2009;8:27, Published online 2009 June 1.10.1186/1475-2840-8-27Search in Google Scholar PubMed PubMed Central
33. Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, et al. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metabol 2007;92:1881–85.10.1210/jc.2006-2643Search in Google Scholar PubMed
34. Cavusoglu E, Ruwende C, Chopra V, Poludasu S, Yanamadala S, et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis 2010;210:226–31.10.1016/j.atherosclerosis.2009.10.034Search in Google Scholar PubMed
©2015 by De Gruyter
